Carlos Del Rio, MD; Richard A. Elion, MD, MA
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Gilead Sciences, Inc.
Carlos Del Rio, MD
Professor and Chair, Hubert Department of Global Health
Rollins School of Public Health, Emory University
Professor of Medicine
Emory University School of Medicine
Director for Clinical Sciences and International Research
Emory Center for AIDS Research
Emory AIDS International Training and Research Program
Dr. Carlos Del Rio is Hubert Professor and Chair of the Hubert Department of Global Health at the Rollins School of Public Health of Emory University and Professor of Medicine at Emory University School of Medicine. He is Director for Clinical Sciences and International Research of the Emory CFAR and Director of the Emory AIDS International Training and Research Program.
Dr. Del Rio is a native of Mexico where he was Executive Director of the National AIDS Council of Mexico (CONASIDA, the Federal agency of the Mexican Government responsible for AIDS Policy throughout Mexico), from 1992 through 1996. He was also a member of the Program Coordinating Board of UNAIDS (1995 -97).
Since joining the faculty at Emory in 1996 he has served in many leadership roles including Chief of the Emory Medical Service at Grady Memorial Hospital (2001 – 2009) and Executive Director of the Hope Clinic of the Emory Vaccine Center (2004 – 2006).
Dr. Del Rio is a Member of the Board of Directors of the International AIDS Society-USA, the HIVMA of the Infectious Diseases Society of America (IDSA) and the IDSA. He is a member of the DHHS Panel for Antiretroviral Guidelines for Adults and Adolescents and member of the Advisory Committee on HIV and STD Prevention and Treatment of the Centers for Disease Control and Prevention and Health Resources and Services Administration. He is Senior Clinical Editor for AIDS Research and Human Retroviruses and Associate Editor of AIDS Clinical Care and member of the editorial board of Journal of AIDS, Women, Children and HIV, and Global Public Health. Dr. Del Rio has been a member of four Institute of Medicine Committees on HIV/AIDS issues (The Ryan White Care Act: Data for Resource Allocation, Planning and Evaluation; Methodological Issus on HIV Prevention Trials; HIV Social Security Disability Criteria, and Data Systems for Monitoring HIV Care). Dr. Del Rio has co-authored 5 books, 30 book chapters and over 200 scientific papers.
Richard A. Elion, MD, MA
Clinical Professor of Medicine
George Washington University, School of Medicine
Senior Policy Advisor
Director of HIV/HCV Clinical and Research Program
Washington Health Institute
Washington, District of Columbia
Dr. Richard Elion is Clinical Professor of Medicine at George Washington University, School of Medicine as well as Director of the HIV/HCV Clinical and Research Program at the Washington Health Institute, in Washington, District of Columbia (DC). Dr. Elion actively sees patients with HIV/AIDS, hepatitis C, and other sexually transmitted diseases. In addition to seeing private patients, he serves as Senior Policy Advisor at Trio Health in Washington, DC. Dr. Elion is the past Director of Clinical Research at Whitman-Walker Health, where he focused on cutting edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, Dr. Elion served as Co-Director of HIV Services at Washington Free Clinic and in various research and clinical capacities in New York and Washington. He received his medical degree from Temple University in Philadelphia, Pennsylvania and completed his internship and residency at Duke University Medical Center in Durham, North Carolina. Dr. Elion also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.
This activity is intended for infectious disease and HIV specialist physicians and other clinicians involved in the care of patients with HIV infection
Statement of Need/Program Overview
Transgender patients face an increased risk of contracting HIV, and for those who are HIV positive, a unique set of challenges in treatment. This population achieves viral suppression less frequently than cisgender populations, making it essential for clinicians to understand the factors that determine this gap and optimal strategies to improve patient care. This case-based, interactive activity focuses on transgender women with HIV, creating a clinical scenario addressing treatment initiation, incorporating gender-affirming hormone therapy into care, adherence, common comorbidities, and strategies to create a gender-affirming practice.
After completing this activity, the participant should be better able to:
- Implement strategies to overcome the barriers to and facilitate the benefits of timely HIV treatment initiation, including consideration of rapid ART protocols
- Describe the HIV treatment considerations unique to transgender women to improve engagement in care and optimize viral suppression
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 65% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 65%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Carlos Del Rio, MD
Consultant/Independent Contractor: Merck & Co., Inc.; Grant/Research Support: NIH/NIADS (Emory CFAR) - grant to institution, NIH/BNIAID (Emory HIV CTU) - grant to institution
Richard A. Elion, MD, MA
Consultant/Independent Contractor: Gilead Sciences, Inc.; Grant/Research Support: Gilead Sciences, Inc., ViiV Healthcare Limited; Honoraria: Gilead Sciences, Inc., ViiV Healthcare Limited; Speaker’s Bureau: Gilead Sciences, Inc., ViiV Healthcare Limited; Other/Royalty (Describe): Works with Trio Health, Inc., who receives grants from Gilead Sciences, Inc., ViiV Healthcare Limited
Lindsay Borvansky; Andrea Funk; Liddy Knight; Ashley Cann; Gena Dolson, MS; Stacey JP Ullman, MS; Jim Kappler, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.